Effect of Prior Chemotherapy Regimens on Rucaparib Treatment in Platinum-Sensitive Recurrent Ovarian Carcinoma

Conference Correspondent  - ESMO Highlights

The randomized, placebo-controlled phase 3 ARIEL3 study showed that patients with platinum-sensitive recurrent ovarian carcinoma who received oral rucaparib (600 mg twice daily) as maintenance treatment following response to platinum-based chemotherapy had significantly improved progression-free survival (PFS) compared with placebo, regardless of their biomarker status.1 In a post-hoc exploratory analysis, Lorusso and colleagues investigated the effect of the number of prior chemotherapy regimens on the primary and secondary end points of investigator-assessed and blinded independent central review–assessed PFS in ARIEL3.2

Predefined cohorts for the analysis included BRCA mutant; BRCA mutant or BRCA wildtype/high loss of heterozygosity; and the intent-to-treat population (ie, all randomized patients). PFS in each cohort was evaluated in subgroups of patients having received either 2 or ≥3 prior chemotherapy regimens.

In each of the predefined cohorts, rucaparib significantly improved PFS compared with placebo, irrespective of the number of prior chemotherapy regimens. The safety profile of rucaparib was consistent between patients who received 2 or ≥3 prior chemotherapy regimens as assessed by the rate of all-grade (100% and 100%) and grade ≥3 (59% and 59%) treatment-emergent adverse events. Dose modifications (ie, treatment interruptions and/or dose reductions due to a treatment-emergent adverse event) were also similar between each subgroup (70% and 74%).

The results of this post-hoc analysis suggest that the improved PFS associated with rucaparib maintenance treatment compared with placebo is not affected by the number of prior chemotherapy regimens received in the 3 predefined cohorts that were evaluated.

References

  1. Coleman RL, et al. Lancet. 2017;390(10106):1949-1961.
  2. Lorusso D, et al. ESMO 2018. Abstract 947P.
Related Items
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO Highlights
Trabectedin/PLD versus Carboplatin/PLD in Recurrent Ovarian Cancer Progressing within 6-12 Months After Last Platinum Line
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Safety and Efficacy of XMT-1536 in Ovarian Cancer: Subgroup Analysis from a Phase 1 Expansion Study
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Maintenance Olaparib plus Bevacizumab for Newly Diagnosed High-Grade Ovarian Cancer: Second Progression-Free Survival
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Real-World Data on Platinum Therapy in High-Grade Serous Ovarian Cancer Patients Progressing After PARP Inhibitor Treatment
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Atezolizumab in Patients with Newly Diagnosed Stage III or Stage IV Ovarian Cancer
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Mirvetuximab Soravtansine in Combination with Carboplatin and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Patient-Reported Outcomes in Patients Receiving Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Nivolumab versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients with Platinum-Resistant Ovarian Cancer: The NINJA Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Individualized Starting Dose of Niraparib to Treat Platinum-Sensitive Recurrent Ovarian Cancer: The NORA Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: